BNTC

Benitec Biopharma's stock has been impacted by several events over the past six months. In November 2025, the company announced concurrent offerings, selling shares in underwritten and registered direct deals, raising approximately $100 million. Equity awards were granted to the CEO and a director in November 2025 and January 2026, respectively. Positive interim Phase 1b/2a results for high-dose BB-301 were announced in March 2026, leading to a stock price increase. Share dilution was identified as a minor risk in May 2026, with total shares outstanding growing by 34.1%. The stock experienced fluctuations in April-May 2026, with a decline in 8 out of 10 days, but gained on May 4 and May 8, 2026. As of May 1, 2026, the share price was $11.95, a 20.60% decline from May 2, 2025.